Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of TM5614 plus tyrosine kinase inhibitors in chronic phase CML
jRCT2031190071Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2019
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of TM5614 in chronic myelogenous leukemia (CML), sponsored by Japan Agency for Medical Research and Development. Started Sep 2019; status: active, not recruiting.
02
Drugs
TM5614
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2031190071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190071.